Panakeia’s PANProfiler AI Cancer Test Gains CE Mark, UKCA Approval

London-based Panakeia has received CE mark certification for its PANProfiler artificial intelligence-based cancer image analysis system.

The software analyzes digital images of breast tumor samples and predicts whether the cancer cells have estrogen or progesterone receptors, indicating if the patient could benefit from HER2 chemotherapy from Genentech’s Herceptin (trastuzumab). HER2-positive breast cancer is highly curable with HER2-targeted therapies.

Founded in 2018 by a former cancer researcher at the University of Cambridge, Pahini Pandya, with AI researcher Pandu Raharja-Liu, Panakeia is focused on the use of AI and machine learning in cancer diagnostics and personalized medicine.